Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

China · Delayed Price · Currency is CNY

40.30

+0.32 (0.80%)

Oct 30, 2026, 3:00 PM CST

Market Cap	26.45B -4.1%
Revenue (ttm)	4.72B -21.2%
Net Income	848.15M -75.8%
EPS	1.10 -75.7%
Shares Out	770.09M
PE Ratio	36.47
Forward PE	30.07
Dividend	4.68 (11.61%)
Ex-Dividend Date	Jul 10, 2026

Volume	5,880,222
Open	39.97
Previous Close	39.98
Day's Range	39.70 - 41.10
52-Week Range	33.83 - 50.95
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2026

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1915

Employees 3,890

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600329

Full Company Profile

Financial Performance

In 2025, SHA:600329's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial Statements